Jupiter Neurosciences, Inc. (JUNS) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues.
Analysis Summary
Jupiter Neurosciences, Inc. reported revenue of $21796 in the most recent fiscal year, growing at a 5-year CAGR of -54.6%.
Trailing-twelve-month margins: gross margin 88.3%, operating margin -151.7%, net margin -142.2%.
At the current price of $2.93, JUNS has negative trailing earnings (P/E not meaningful) and an ROE of 7.47%. Market capitalisation stands at $1M.
Balance sheet quality for JUNS: current ratio of 0.7, net debt of $1.5M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $2.93 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -4.27 |
| EV / EBITDA | -0.19 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 747.33% |
| Return on Invested Capital | -709.40% |
| Return on Assets | -247.39% |
| Gross Margin | 88.34% |
| Operating Margin | -15166.68% |
| Net Margin | -14220.12% |
Financial Health
| Debt / Equity | -4.78 |
| Current Ratio | 0.66 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| JUNS | Jupiter Neurosciences, Inc. | $1M | 7.5% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -42.09% |
| 3 months | -83.59% |
| Year-to-date | -96.17% |
| 1 year | -97.38% |
52-Week Range
| 52-week High | $138.00 |
| 52-week Low | $2.88 |
| Avg Volume (90d) | 745K |
Related companies: ABVC · ALGS · FGEN · GNTA · GRCE · KZR · MRSN
Explore sector: Healthcare · Biotechnology
More sections of JUNS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks